These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851 [Abstract] [Full Text] [Related]
27. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774 [Abstract] [Full Text] [Related]
28. PDE Inhibitors for the Treatment of Schizophrenia. Snyder GL, Vanover KE. Adv Neurobiol; 2017 Mar; 17():385-409. PubMed ID: 28956340 [Abstract] [Full Text] [Related]
33. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Krystal JH, Anand A, Moghaddam B. Arch Gen Psychiatry; 2002 Jul; 59(7):663-4. PubMed ID: 12090822 [No Abstract] [Full Text] [Related]